Luis E Fayad

Luis E Fayad

UNVERIFIED PROFILE

Are you Luis E Fayad?   Register this Author

Register author
Luis E Fayad

Luis E Fayad

Publications by authors named "Luis E Fayad"

Are you Luis E Fayad?   Register this Author

88Publications

2886Reads

34Profile Views

CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.

Leuk Lymphoma 2019 Sep 18:1-9. Epub 2019 Sep 18.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1663418DOI Listing
September 2019

Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience.

Clin Lymphoma Myeloma Leuk 2019 Jul 4. Epub 2019 Jul 4.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.06.013DOI Listing
July 2019

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Blood 2019 Jun 17;133(26):2800-2802. Epub 2019 May 17.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019000888DOI Listing
June 2019

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.

Leuk Lymphoma 2019 Jun 24:1-8. Epub 2019 Jun 24.

a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1627535DOI Listing
June 2019

Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.

Clin Lymphoma Myeloma Leuk 2019 Apr 3;19(4):244-250. Epub 2019 Jan 3.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.016DOI Listing
April 2019

Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.

Leuk Lymphoma 2018 12 26;59(12):2896-2903. Epub 2018 Apr 26.

b Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1460825DOI Listing
December 2018

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.

Ophthalmic Plast Reconstr Surg 2018 Aug 17. Epub 2018 Aug 17.

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001215DOI Listing
August 2018

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Br J Haematol 2017 12 9;179(5):851-854. Epub 2016 Aug 9.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063086PMC
December 2017

Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma.

Ophthalmic Plast Reconstr Surg 2017 Sep/Oct;33(5):355-360

*Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, †Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, ‡Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, Galveston, Texas, U.S.A.; §Narayana Nethralaya, Narayana Health City, Bangalore, India; ‖Department of Lymphoma and Myeloma, ¶Department of Radiation Oncology, and #Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000000789DOI Listing
September 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J Natl Compr Canc Netw 2016 09;14(9):1067-79

From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0117DOI Listing
September 2016

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

Haematologica 2015 Nov 6;100(11):e454-7. Epub 2015 Aug 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.131144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825296PMC
November 2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087315PMC
October 2015

Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.

Int J Radiat Oncol Biol Phys 2015 May 5;92(1):122-9. Epub 2015 Mar 5.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.014DOI Listing
May 2015

Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

J Clin Oncol 2014 Jan 9;32(2):114-20. Epub 2013 Dec 9.

Roberto N. Miranda, Rashmi Kanagal-Shamanna, Luis E. Fayad, Summer E. Hanson, John T. Manning Jr, Zijun Y. Xu-Monette, Patricia Fox, Roland L. Bassett, Ken H. Young, L. Jeffrey Medeiros, The University of Texas MD Anderson Cancer Center; Alonso R. Miranda, University of Houston, Houston; Eid Mustafa, Plastic and Reconstructive Surgery, Wichita Falls; Steven Sanchez, Pathology Associates of Tyler, Tyler, TX; Mitual B. Amin, Oakland University William Beaumont School of Medicine, Royal Oak, MI; Nisreen Haideri, Saint Lukes Cancer Institute, Kansas City, MO; Govind Bhagat, Columbia University Medical Center, New York Presbyterian Hospital and Herbert Irving Comprehensive Cancer Center, New York, NY; Glen S. Brooks, Tufts University, Longmeadow; Ephram P. Hochberg, Massachusetts General Hospital; Matthew J. Carty, Brigham & Women's Hospital, Boston, MA; David A. Shifrin, Advocate Medical Group Plastic Surgery, Oak Lawn, IL; Dennis P. O'Malley, Clarient Laboratories/GE Healthcare, Aliso Viejo, CA; Shiyong Li, Emory University Hospital, Atlanta, GA; John A. Keech Jr, MultiCare Regional Cancer Center, MultiCare Health Systems, Tacoma, WA; Jorge J. Castillo, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI; Dongjiu Ye, Bioreference Laboratories, Elmwood Park, NJ; Douglas Clark, New Mexico Cancer Center, Albuquerque, NM; Tariq N. Aladily, The University of Jordan, Amman, Jordan; H. Miles Prince, Chan Y. Cheah, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Daphne de Jong, Vrije Universiteit Medical Center; Jan Paul de Boer, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Carlos E. Bacchi, Gabriela Gualco, Consultoria em Patologia, Botucatu, São Paulo, Brazil; Brady E. Beltran, Edgardo Rebagliati Martins Hospital, Lima, Peru; Zaher Chakhachiro, American University of Beirut Medical Center, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.7911DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062709PMC
January 2014

Recent advances in de novo CD5+ diffuse large B cell lymphoma.

Am J Hematol 2013 Sep 5;88(9):798-802. Epub 2013 Jun 5.

Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23467DOI Listing
September 2013

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Mod Pathol 2012 Jan 14;25(1):145-56. Epub 2011 Oct 14.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2011.147DOI Listing
January 2012

Marginal zone lymphomas: factors that affect the final outcome.

Cancer 2010 Sep;116(18):4291-8

Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25325DOI Listing
September 2010

Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma.

Leuk Lymphoma 2010 Sep;51(9):1649-57

Division of Hematology-Oncology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2010.49
Publisher Site
http://dx.doi.org/10.3109/10428194.2010.494315DOI Listing
September 2010

Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.

Curr Hematol Malig Rep 2009 Oct;4(4):218-24

Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit #429, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-009-0029-yDOI Listing
October 2009

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Cancer 2008 Feb;112(4):831-6

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.23237
Publisher Site
http://dx.doi.org/10.1002/cncr.23237DOI Listing
February 2008

[High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].

Med Clin (Barc) 2008 Jan;130(2):60-5

Servicio de Oncología Médica, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid, Madrid, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1157/13115028DOI Listing
January 2008

Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature.

Am J Hematol 2007 Aug;82(8):725-8

Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.20852DOI Listing
August 2007

K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis.

Blood 2007 Mar 7;109(5):2174-82. Epub 2006 Nov 7.

Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-02-003178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1801039PMC
March 2007

Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.

Cancer 2007 Jan;109(1):77-83

Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22389DOI Listing
January 2007

Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.

J Infect Dis 2006 Nov 6;194(10):1394-7. Epub 2006 Oct 6.

Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/508493DOI Listing
November 2006

Stage III follicular lymphoma: long-term follow-up and patterns of failure.

Int J Radiat Oncol Biol Phys 2003 Nov;57(3):748-54

Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(03)00641-2DOI Listing
November 2003

Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.

Cancer J 2002 Sep-Oct;8(5):377-83

Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2002/09000/Radiother
Web Search
April 2003